Insider Trading February 10, 2026 11:46 AM

Bankwell Financial principal accounting officer disposes of $15.8k in shares as company reports Q4 beat

Fusaro records a modest sale and a zero-cost grant in same filing amid better-than-expected fourth-quarter results and mixed market reaction

By Avery Klein
Share
Twitter Reddit Facebook LinkedIn
BWFG

Angelo G. Fusaro, Principal Accounting Officer at Bankwell Financial Group, Inc. (NASDAQ:BWFG), sold 316 shares on February 9, 2026 for $49.88 per share, totaling $15,762, and in the same Form 4 reported receipt of 414 shares granted under the 2022 Stock Plan at a $0 price. Bankwell posted fourth-quarter 2025 results that exceeded analyst expectations on both EPS and revenue, yet the stock slipped in pre-market trading and no analyst upgrades or downgrades were specified in the filing.

Bankwell Financial principal accounting officer disposes of $15.8k in shares as company reports Q4 beat
BWFG
Summarize with
ChatGPT Perplexity Claude Grok Gemini

Key Points

  • Angelo G. Fusaro sold 316 shares on February 9, 2026 at $49.88 per share, totaling $15,762, as reported in a Form 4 filing with the SEC.
  • Fusaro also received 414 shares granted under the 2022 Bankwell Financial Group, Inc. Stock Plan at a $0 grant price, with a reported total value of $0.
  • Bankwell reported Q4 2025 EPS of $1.36 and revenue of $30.32 million, both above analyst expectations, but the stock fell in pre-market trading and no specific analyst upgrades or downgrades were disclosed.

Angelo G. Fusaro, who serves as Principal Accounting Officer at Bankwell Financial Group, Inc. (NASDAQ:BWFG), recorded an insider sale and a concurrent grant in a Form 4 filed with the Securities and Exchange Commission. The filing shows Fusaro sold 316 shares of common stock on February 9, 2026, at $49.88 per share, producing gross proceeds of $15,762.

In the same SEC disclosure, Fusaro reported acquiring 414 shares of Bankwell common stock. Those shares were issued under the 2022 Bankwell Financial Group, Inc. Stock Plan at a grant price of $0, and the filing lists the total value of those shares as $0.


Separately, Bankwell released its financial results for the fourth quarter of 2025, reporting an earnings per share (EPS) of $1.36, ahead of the $1.19 analysts were expecting. The company also posted revenue of $30.32 million, topping the consensus projection of $28.06 million. The EPS result represents a 14.29% surprise relative to expectations, underscoring that the quarter outpaced forecasts on both earnings and top-line metrics.

Despite the stronger-than-expected operating results, Bankwell's shares experienced a decline in pre-market trading following the earnings release. The reporting noted that various analyst firms have taken note of the results, but the public record did not include any specific analyst upgrades or downgrades tied to the announcement.

The Form 4 details and the company’s published quarterly figures form the basis of the public record described in the filing. The disclosure links an insider transaction and equity compensation grant to a quarter in which the company reported better-than-expected earnings and revenue, while market response in pre-market trading was muted-to-negative and the filing did not indicate any formal changes in analyst recommendations.

Where the filing or the public releases are silent, there is no additional information on the motivations behind the insider sale or the intended use of the granted shares. The Form 4 and the company’s quarterly disclosure together provide the factual account of the transaction, the grant and the reported quarterly performance.

Risks

  • Market reaction risk - Despite stronger-than-expected EPS and revenue for Q4 2025, Bankwell’s stock declined in pre-market trading, reflecting uncertain investor sentiment in the financials sector.
  • Analyst coverage uncertainty - The report noted attention from multiple analyst firms but did not record any specific upgrades or downgrades, leaving the direction of formal analyst recommendations unclear for investors.
  • Limited disclosure on insider intent - The Form 4 records the sale and the zero-cost grant but does not provide the motivations behind Fusaro’s transactions, which creates uncertainty about insider intent.

More from Insider Trading

Cavco Industries CFO Aden Allison Executes Pre-arranged Sale of 1,473 Shares Jun 26, 2026 Spyre Therapeutics CFO Burrows Executes $1.3M Stock Sale Amid Clinical Momentum Jun 26, 2026 Natera Legal Officer Daniel Rabinowitz Executes $8.45 Million Share Sale Under Pre-Arranged Plan Jun 26, 2026 Natera Director Herm Rosenman Offloads $4.13M in NTRA Shares Jun 26, 2026 NextNav COO Susan Insley Executes Stock Sale Under Pre-Existing Trading Plan Jun 26, 2026